Nemaura Med Inc Stock Price, News & Analysis

Nemaura Medical (NASDAQ: NMRD) announced the appointment of Dr. Osama Hamdy as a consultant on their advisory board. Dr. Hamdy, a senior endocrinologist and medical director at the Joslin Diabetes Center, will advise on key opinion leader studies focused on diabetes and metabolic health using Nemaura's glucose monitoring technology. The collaboration aims to enhance patient health through non-invasive treatments, leveraging Dr. Hamdy's expertise in obesity management and digital health. Nemaura's products, including sugarBEAT^®, are positioned in a growing global diabetes market projected to reach $59 billion by 2025.

Nemaura Medical (NASDAQ: NMRD), a medical technology firm, announced that CEO Faz Chowdhury, Ph.D., will present at the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled virtually from September 13 – 15, 2021. The corporate presentation will be available starting September 13 at 7:00 AM ET. Investors can register for the conference on the official website. Nemaura specializes in non-invasive diagnostic devices, including sugarBEAT®, a CE-approved continuous glucose monitor, and proBEAT™, an AI-driven health service.

Nemaura Medical (Nasdaq: NMRD) announced a business update and financial results for Q1 FY2022, ending June 30, 2021. The company launched the BEAT^®diabetes service, targeting over 113 million people with diabetes and pre-diabetes in the U.S. It received positive feedback from the UK soft launch of sugarBEAT^®, generating a purchase order for 200,000 sensors. Financially, operating expenses were approximately $1.6 million, with cash reserves of $31.3 million as of June 30, 2021. The company anticipates revenue recognition from its licensee starting in Q3 2021.

Nemaura Medical (Nasdaq: NMRD) announced a corporate overview presentation by CEO Faz Chowdhury, Ph.D. at the Access to Giving Virtual Investor Conference, scheduled for July 13, 2021, at 1:00pm ET.

The company is focused on non-invasive wearable diagnostic devices, such as sugarBEAT®, a glucose monitor approved in the EU. Nemaura is also targeting the substantial global diabetes market projected to reach $59 billion by 2025. For more details, investors can register for the conference.

Nemaura Medical (NASDAQ: NMRD) presented its licensed Why WAIT program at the American Diabetes Association’s 81st Annual Scientific Sessions. The program, developed by the Joslin Diabetes Center, is aimed at managing weight and diabetes. A study showed that both virtual and in-person programs led to comparable outcomes, including ~7% weight loss and ~1% reduction in A1C. The company integrates this program into its BEAT diabetes initiative, utilizing a partnership with Healthimation.

CEO Dr. Faz Chowdhury emphasized the importance of this validation for scalable growth in diabetes management.

Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company, reported a business update and financial results for the fiscal year ending March 31, 2021. Key highlights include positive user feedback from the UK soft launch of sugarBEAT^®, with a purchase order for 200,000 sensors and a forecast of 2 million sensors over two years. The company secured $25 million in non-dilutive funding and launched BEATdiabetes.life in the U.S. R&D expenses decreased to $1.55 million, while the net loss rose to $6.26 million, driven by interest charges on debt funding.

Nemaura Medical (NASDAQ: NMRD) will present a corporate overview at the LD Micro Virtual Invitational Conference from June 8-10, 2021. CEO Faz Chowdhury, Ph.D., is scheduled to present on June 9 at 1:00 PM ET, Track 3. Investors can register to watch the presentation here. Nemaura specializes in non-invasive wearable devices for diabetes management, including the CE mark approved sugarBEAT® and the AI-enhanced proBEAT™.

Nemaura Medical (NASDAQ: NMRD) announced its participation in the Summer Solstice Best Ideas Conference, running from June 1-4, 2021. CEO Faz Chowdhury, Ph.D. will present on June 2 at 4:00 PM ET, with the presentation available for live webcast and replay. Nemaura Medical focuses on non-invasive wearable diagnostic devices, including sugarBEAT®, a continuous glucose monitor, and proBEAT™, an AI-driven health product.

The company aims to capture significant markets in Type 2 diabetes and pre-diabetes, projected to reach nearly $59 billion and $50 billion respectively by 2025.

Nemaura Medical (NASDAQ: NMRD) announced progress with the German regulatory authority (GBA) for reimbursement of its sugarBEAT® device. GBA determined that sugarBEAT does not require review and will directly go to the National Association of Statutory Health Insurance Funds for catalog listing, expediting the process. CEO Dr. Faz Chowdhury emphasized the significance of this milestone and mentioned ongoing negotiations for marketing partnerships in Germany. Nemaura is also commercializing proBEAT™, a non-invasive glucose monitoring product, targeting a growing diabetes market.